A production laboratory for CAR-T cell therapies in Nanjing, China, on June 9. The world’s strictest regulatory agencies increasingly view Chinese drugs as generally promising enough to justify devoting extra resources to speed up their review.
Photographer: Qilai Shen/Bloomberg
China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline
Chinese biotech's advance has been as ferocious as the nation's breakthrough efforts in AI and EVs, eclipsing the EU and catching up to the US
The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation.
The number of novel drugs in China — for cancer, weight-loss and more — entering into development ballooned to over 1,250 last year, far surpassing the European Union and nearly catching up to the US’s count of about 1,440, an exclusive Bloomberg News analysis showed.